Skoči na glavni sadržaj

Pregledni rad

New anticoagulant medications

Silva Zupančić Šalek ; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Ana Boban ; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska
Dražen Pulanić ; Referentni centar za hemofiliju i trombofiliju, Odjel za trombozu i hemostazu, Zavod za hematologiju, Klinika za unutarnje bolesti, KBC Zagreb, Zagreb, Hrvatska


Puni tekst: hrvatski pdf 260 Kb

str. 366-369

preuzimanja: 3.218

citiraj


Sažetak

Currently available anticoagulant medications are effective for the prevention and treatment of thromboembolic diseases. However, they have certain drawbacks which do not allow them to be the “ideal anticoagulants”. The decision regarding anticoagulant therapy is a very complex process, especially nowadays when many new anticoagulants are available. Such new anticoagulant drugs are developed and produced to target mostly a single coagulation factor, and they have a predictable dose response. The most important anticoagulants are direct thrombin inhibitors and factor Xa inhibitors. Selective inhibitors of specific coagulation factors represent a new class of anticoagulant agents. Comparing to the traditional, classic anticoagulant medications, the new anticoagulants are potentially more effective, safer and easier to use. The possible limitation of new anticoagulants is the lack of specific antidotes. However, they have short plasma half life, making their neutralization easier.

Ključne riječi

anticoagulant medications; apixaban; dabigatran etexilat; fondaparinux; rivaroxaban

Hrčak ID:

76668

URI

https://hrcak.srce.hr/76668

Datum izdavanja:

1.12.2011.

Podaci na drugim jezicima: hrvatski

Posjeta: 4.872 *